Ajinomoto Bio-Pharma Services vs Novartis: CDMO Comparison

How does Ajinomoto Bio-Pharma Services compare to Novartis?

As of Oct 2026, Ajinomoto Bio-Pharma Services: no FDA inspections on file, 1 EMA/MHRA GMP certificate. Signal Score 83.5. Novartis: 17 FDA inspections (including 9 NAI, 8 VAI and 0 OAI), 51 EMA/MHRA GMP certificates. Signal Score 85.4. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Ajinomoto Bio-Pharma Services and Novartis on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

San Diego, CA · Osaka, JP
Signal Score
84/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
0
Capacity
—
Modalities
Oligonucleotide, Biologics, AAV
Basel, Switzerland
Signal Score
85/100
Quality (FDA + GMP)
97/100
FDA inspections
17
— NAI / VAI / OAI
9 / 8 / 0
FDA warning letters
0
EMA GMP certificates (active)
50
MHRA GMP certificates (compliant)
1
Clinical programs (matched)
137
Capacity
—
Modalities
CAR-T, Gene Therapy

Key differences

  • Novartis has more FDA inspections on record (17 vs 0) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Novartis holds 50 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
  • Novartis appears as a manufacturing partner on more matched clinical programs (137 vs 0) — a broader sponsor book.

Across the cross-modality scorecard, Novartis carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Ajinomoto Bio-Pharma Services vs Novartis

How does Ajinomoto Bio-Pharma Services compare to Novartis?

On CDMO Signal's composite Signal Score, Ajinomoto Bio-Pharma Services is 84/100 and Novartis is 85/100; Ajinomoto Bio-Pharma Services has 0 FDA inspections on record vs 17 for Novartis; European coverage is 1 active EMA+MHRA certificate for Ajinomoto Bio-Pharma Services vs 51 for Novartis. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Novartis?

Both Ajinomoto Bio-Pharma Services and Novartis maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Novartis has 17.

How do Ajinomoto Bio-Pharma Services and Novartis compare on European GMP coverage?

Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Novartis holds 50 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Ajinomoto Bio-Pharma Services or Novartis?

Ajinomoto Bio-Pharma Services is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Novartis is matched to 137. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

What does the Signal Score gap mean in practice?

Ajinomoto Bio-Pharma Services carries a Signal Score of 84/100 and Novartis carries 85/100 — essentially tied for Novartis. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Ajinomoto Bio-Pharma Services and Novartis for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.